Brez internetne povezave — prikazana je shranjena različica strani.

Innate Pharma

FREUR
← Na filter delnic

Innate Pharma (US:IPHYF) — Biotechnology: Biological Products (No Diagnostic Substances). Število borz, na katerih se trgujejo delnice družbe: 3. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.

O podjetju

Spletna stran
innate-pharma.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sedež
MARSEILLE, France
Izvršni direktor
Jonathan E. Dickinson
Zaposleni
120
Ustanovljena
1999
Delnice v obtoku
111.7 mio.
Prosto prenosljive delnice
70.45 mio.
Tržna kapitalizacija
146.33 mio. EUR
Notranje osebe
17.46%
Institucionalni vlagatelji
10.86%
Panoga (SIC)
Biological Products, (No Diagnostic Substances)
Pravna oblika
K65D
ISIN
FR0010331421
LEI
9695002Y8420ZB8HJE29
FCF
−52.9 mio. EUR
Dolg
0
Dobiček in FCF — za 12 mesecev do 31.12.2025 (najnovejše poročilo podjetja).
Opis

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Borze in oznake

BorzaOznakaValutaCenaVrsta
PA Euronext ParisIPH glavnaEUR1.302 +2.84%navadne delnice
LSE London Stock Exchange0EVI IOBEUR1.304 +2.27%navadne delnice
US USA StocksIPHYF OTCUSD1.5092 -8.53%navadne delnice

Cena v 3 mesecih

PA:IPH · EUR
US:IPHYF v zadnjih 3 mesecih ni bil trgovan — graf prikazuje PA:IPH
dan rasti dan padcaPremaknite miško / tapnite dan — otvoritvena, zaključna, najvišja in najnižja cena

Novice ta teden

V zadnjem tednu ni novic. Najnovejše novice: 17.09.2026.

oglas

Največji imetniki

ImetnikDeležDelniceDatum poročila
ETF Series Solutions-Ran…0.08%72 6952025-02-28
Lion Point Capital, LP0.07%81 1512026-06-30
Morgan Stanley0.04%43 5242026-06-30
Smartharvest Portfolios,…0.02%23 7502026-06-30
Dimensional ETF Trust-Di…0.02%23 2772026-01-31
Xtx Topco Ltd0.01%15 1302026-06-30
Citadel Advisors Llc0.01%12 4412026-06-30
Jane Street Group, LLC0.01%10 3102026-06-30
Rhumbline Advisers0%4 7192026-06-30
UBS Group AG0%1 3632026-06-30
Farther Finance Advisors…0%212026-06-30
Gamma Investing LLC0%92026-06-30